Immunomedics (IMMU) Issues Encouraging Update for Epratuzumab w/ 90Y on ... StreetInsider.com (subscription) Immunomedics, Inc. (Nasdaq: IMMU) reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90 (90Y), to a combination of rituximab and CHOP chemotherapy (R-CHOP), the standard of care for patients with diffuse large B-cell ... Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in ... |
